Overall, we observed that GDF15 gene editing and PD1 antibodies have a large synergistic therapeutic effect and that SNCSS(Cas9/sgGDF15) can promote the therapeutic efficacy of anti‐mPD1 therapy in HCC. The gene discussed is GDF15; the disease is hepatocellular carcinoma.